AGENUS INC — Director's Dealing 2015

May 27, 2015

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AGENUS INC (AGEN)
CIK: 0001098972
Period of Report: 2015-05-27

Reporting Person: Malik Shahzad (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2015-05-27	Common Stock	J	1587302	$6.30	Acquired	1587302	Indirect

Footnotes

F1: Advent Life Sciences LLP and Advent Life Sciences Fund II LP acquired 54,556 and 1,532,746 shares of Agenus Inc. common stock, respectively, in a public offering that closed on May 27, 2015. Advent Life Sciences LLP is the General Partner of Advent Life Sciences Fund II LP. Dr. Malik is a General Partner of Advent Life Sciences LLP and shares voting and investment power over the shares, and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.